Selective serotonin-reuptake inhibitors for the treatment of hot flashes

被引:8
|
作者
De Sloover Koch, Y
Ernst, ME
机构
[1] Univ Iowa, Div Clin & Adm Pharm, Coll Pharm, Iowa City, IA 52242 USA
[2] Dept Vet Affairs Med Ctr, Ambulatory Care Clin Pharm Specialist, Iowa City, IA USA
关键词
antidepressants; hot flashes; selective serotonin-reuptake inhibitors;
D O I
10.1345/aph.1D512
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review the literature evaluating the use of selective serotonin-reuptake inhibitors (SSRIs) for the treatment of hot flashes. DATA SOURCES: Biomedical literature was accessed through MEDLINE (1966-June 2003), MID Consult, and references of reviewed articles. Key search terms used were hot flashes, vasomotor symptoms, antidepressants, and SSRIs. DATA SYNTHESIS: Recent evidence from the Women's Health Initiative precludes the use of traditional hormonal therapy in some women. Nonhormonal therapies are possible options, but conflicting evidence of efficacy exists. CONCLUSIONS: Although further studies are warranted, preliminary data suggest that SSRIs are generally modestly successful in reducing the frequency and severity of hot flashes.
引用
收藏
页码:1293 / 1296
页数:4
相关论文
共 50 条
  • [31] Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn
    Chambers, CD
    Hernandez-Diaz, S
    Van Marter, LJ
    Werler, MM
    Louik, C
    Jones, KL
    Mitchell, AA
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06): : 579 - 587
  • [32] Use of Selective Serotonin-Reuptake Inhibitors during Pregnancy and the Risk of Clubfoot
    Yazdy, Mahsa M.
    Mitchell, Allen M.
    Louik, Carol
    Werler, Martha M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 376 - 376
  • [33] Influence of serotonin related genes on tamoxifen induced hot flashes and responsiveness to selective serotonin reuptake inhibitors.
    Hwang, J
    Jin, Y
    Storniolo, AM
    Hayes, DF
    Li, L
    Stearn, V
    Skaar, TC
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P42 - P42
  • [34] SELECTIVE SEROTONIN-REUPTAKE INHIBITORS ALTER AROMATASE ACTIVITY IN TROPHOBLAST CELLS
    Hudon-Thibeault, Andree-Anne
    Sanderson, J. Thomas
    Vaillancourt, Cathy
    PLACENTA, 2018, 69 : E66 - E66
  • [35] Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects
    Alwan, Sura
    Reefhuis, Jennita
    Rasmussen, Sonja A.
    Olney, Richard S.
    Friedman, Jan M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (26): : 2684 - 2692
  • [36] Use of Selective Serotonin-Reuptake Inhibitors During Pregnancy and the Risk of Clubfoot
    Yazdy, Mahsa M.
    Mitchell, Allen A.
    Louik, Carol
    Werler, Martha M.
    EPIDEMIOLOGY, 2014, 25 (06) : 859 - 865
  • [37] Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization
    Clabault, Helene
    Flipo, Denis
    Guibourdenche, Jean
    Fournier, Thierry
    Sanderson, J. Thomas
    Vaillancourt, Cathy
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 349 : 8 - 20
  • [38] Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?
    Hoirisch-Clapauch, Silvia
    Nardi, Antonio E.
    Gris, Jean-Christophe
    Brenner, Benjamin
    THROMBOSIS RESEARCH, 2014, 134 (01) : 11 - 16
  • [39] Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment
    van Geffen, Erica C. G.
    van Hulten, Rolf
    Bouvy, Marcel L.
    Egberts, Antoine C. G.
    Heerdink, Eibert R.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (02) : 218 - 225
  • [40] Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns
    Dubnov-Raz, Gal
    Juurlink, David N.
    Fogelman, Rami
    Merlob, Paul
    Ito, Shinya
    Koren, Gideon
    Finkelstein, Yaron
    PEDIATRICS, 2008, 122 (03) : E710 - E715